New Eye Drop Treatment for Wet Age-Related Macular Degeneration
Part of Eyes & vision clinical trials.
This study tests a new experimental eye drop (EYC-0305) for wet AMD, a common cause of vision loss in older adults. The goal is to see if it can slow or prevent further damage to central vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years or older
- You have been diagnosed with neovascular (wet) AMD—the type where abnormal blood vessels grow under the retina
- You can attend clinic visits and follow study procedures
- You don't have an allergy to the study drug or fluorescein dye (used for eye imaging)
- Your diabetes (if you have it) is well controlled with current treatment
- You have not had a stroke or heart attack in the past 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new eye drop treatment for people with wet age-related macular degeneration (AMD) who have already been treated with standard injections. The goal is to see if this new treatment can help maintain or improve vision and reduce the need for injections.
This trial tests a new eye drop called PAN-90806 in healthy people to see if it is safe and how the body handles it. Participants will receive the eye drops and be closely monitored.
This trial tests a new eye injection called AIV007 to see if it can safely treat wet age-related macular degeneration (AMD). It's for people who have already had treatment that worked before, and it might offer a different way to deliver the medicine.
This study tests whether a new eye injection called ABP 938 works as well as or better than the current standard treatment (Eylea) for wet age-related macular degeneration—a condition that causes vision loss in the center of your sight. You would receive injections into your eye every month for a year.
This trial tests a new eye drop called NT-101 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if the drops can improve vision and reduce fluid in the eye, possibly as a less invasive alternative to injections.
This study tests an eye drop solution designed to treat wet age-related macular degeneration (AMD), a condition that causes blurry vision due to abnormal blood vessel growth. The treatment aims to reduce fluid and improve vision without the need for frequent eye injections.
Hear when a new Neovascular (Wet) Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.